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The VZV/IE63-specific T cell response
prevents herpes zoster in
fingolimod-treated patients
ABSTRACT
Objective: To assess longitudinally the antiviral immune response of T cells from patients with
multiple sclerosis (MS) treated with fingolimod (FTY) vs other disease-modifying treatments
(DMTs).
Methods:We assessed cellular immune responses specific to influenza virus (FLU), JC virus (JCV),
and varicella-zoster virus (VZV) using quantification of interferon-g secretion by enzyme-linked
immunospot in patients with MS on FTY (n5 31), including 2 with herpes zoster (HZ), natalizumab
(n 5 11), and other DMTs (n 5 11). We used viral lysates for FLU and VZV and a pool of peptides
for FLU, JCV (VP-1), and VZV (IE63).
Results: Besides an expected drop of T cells, we found that, proportionally to the number of CD31
T cells, only FTY-treated patients with MS exhibited an increased VZV/IE63-specific T cell
response peaking 6 months into treatment, a response that returned to baseline after 12 and
24 months. Two FTY-treated patients developed an HZ 6 months into treatment, coinciding with
an absent VZV/IE63-specific T cell response. However, cellular immune responses specific to
VZV lysate, JCV, and FLU (lysate and pool of peptide epitopes) were similar between all 3
categories (FTY, natalizumab, and other DMTs) of study patients.
Conclusions: FTY-treated patients with MS exhibit an increased VZV/IE63-specific cellular
immune response after 6 months of treatment. FTY-treated patients who develop an HZ are
not able to mount such a response, suggesting that a T cell response directed against this viral
protein may be key in preventing the occurrence of HZ. Neurol Neuroimmunol Neuroinflamm
2016;3:e209; doi: 10.1212/NXI.0000000000000209
GLOSSARY
DMT5 disease-modifying treatment; ELISPOT5 enzyme-linked immunospot; FLU5 influenza virus; FTY5 fingolimod;HZ5
herpes zoster; IFN-g5 interferon-g; JCV 5 JC virus;MS 5multiple sclerosis; NTZ5 natalizumab; PBMC 5 peripheral blood
mononuclear cell; SFC 5 spot-forming cell; VZV 5 varicella-zoster virus.
Fingolimod (FTY), a treatment of relapsing-remitting multiple sclerosis (MS), is thought to be
active by specifically trapping naive and central memory T cells within the lymph nodes, with, as
a consequence, a lymphopenia.1 There are scarce reports of a putative association of FTY with
cryptococcal meningitis,2 herpes simplex virus 1 infection,3,4 and progressive multifocal leuko-
encephalopathy5; however, the overall incidence is clearly very low. Thus, the reported overall
incidence of infections does not seem to be significantly higher in patients receiving FTY as
compared to control study participants. By contrast, the occurrence of varicella-zoster virus
(VZV) is significantly increased in FTY-treated patients.6,7 Authors have reported a reduction in
the frequency of interferon-g (IFN-g)-secreting VZV-specific T cells in FTY-treated patients 3
months after treatment initiation, but this difference disappeared when the CD31 T cell count
was normalized.8 Thus, the question of whether there is a dysregulated VZV-specific T cell
response in FTY-treated patients with MS remains open. Furthermore, it is unknown whether
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the increased occurrence of herpes zoster (HZ)
in these patients may be related to the VZV-
specific cellular immune response.
In an attempt to answer these questions, we
studied longitudinally the viral-specific cellular
immune response against VZV, influenza virus
(FLU), and JC virus (JCV) of patients with MS
on FTY and on other disease-modifying treat-
ments (DMTs) and in 2 FTY-treated patients
with MS who presented an HZ.
METHODS Patients We enrolled 53 patients with relapsing-
remitting MS (table 1) who were treated with (1) FTY (n 5 31),
including 2 patients who developed VZV infection while receiving
FTY (table 2); (2) natalizumab (NTZ) (n 5 11); and (3) other
DMTs (IFN-b [n5 8], glatiramer acetate [n5 2], teriflunomide
[n5 1]). None of them was ever vaccinated against VZV, and all of
the FTY-treated patients with MS exhibited anti-VZV antibodies
before treatment initiation (table 1). The diagnosis of MS was made
using the revised McDonald criteria. Blood samples were drawn
just before the first DMT administration (T0) and then at 6, 12,
and 24 months (T6, T12, and T24, respectively) into treatment or
until interruption of the treatment. Peripheral blood mononuclear
cells (PBMCs) were isolated and frozen as previously described in
detail.9
Standard protocol approvals, registrations, and patient
consents. This study was accepted by our institution’s review
board (protocol 172/13) and all participants gave their written
informed consent before study initiation.
Enzyme-linked immunospot assay. To detect interferon-g–
secreting activated T cells specific to VZV, JCV, or FLU, we used
an enzyme-linked immunospot (ELISPOT) assay as described
previously.9 Conditions used were as follows: medium only
(negative control); phytohemagglutinin lectin (positive control,
5 mg/mL, used as a saturating condition); JCV VP1 pools of
sixty-nine 15-mer peptides, overlapping by 10 amino acids,
encompassing the whole VP1 protein, able to elicit a CD41 as
well as a CD81 T cell response9 (10 mg/mL); VZV peptide pool
of sixty-seven 15 mers, overlapping by 11 amino acids, and
covering the whole sequence of the immunodominant IE6310–12
(VZV pool, JPT peptides, 5 mg/mL), thus able to elicit CD41 as
well as CD81 T cell response; FLU CD81-restricted 9-mer
peptide epitopes13 (FLU pool, 1 mg/mL), as well as VZV and
FLU viral lysates (TebuBio, ABI Inc., 1 mg/mL). Spot counts and
mean responses were generated as previously described.9 Briefly,
all conditions were performed in triplicate and a mean of the
results was calculated for each condition. Responses were
initially expressed as net spot-forming cells (SFCs) per 106
PBMCs. The assay was considered valid if the SFCs, in the
absence of peptide (i.e., negative control), were fewer than 40
per 106 cells. Validated background values were subtracted from
the peptide-stimulated data before analysis. Of note, to take into
account the lymphopenic effect of FTY, all SFCs were normalized
to 106 CD31 T cells, whose frequency was determined by flow
cytometry as described previously.13
Statistical analysis. The effect of the group or of treatment
duration was assessed in a Kruskal–Wallis analysis of variance.
The p values obtained from these analyses of variance are
henceforth referred to as pKW. If the effect of the treatment
duration reached significance, the differences between immune
responses measured at T0 and various subsequent time points
were analyzed with the nonparametric paired Wilcoxon ranked
test. A Bonferroni correction was performed to take into
account the comparisons performed at multiple time points
(T0 vs T6, T0 vs T12, T0 vs T24). These stringent statistical
tests were performed to ensure the robustness of any differ-
ences found. However, considering the relatively low number
Table 1 Clinical data of study patients with multiple sclerosis
Age at
study
entry, y Sex
Disease
duration, y
EDSS
score
Total no. relapses
before treatment
onset Previous treatment
No. patients
reaching time
point
VZV serology index
before treatment
introduction
FTY cohort
(n 5 29)
40/14.5 21 F/8 M 9/10.5 1.5/0.5 3/4 15 IFN-b; 4 GA; 1 NTZ;
2 cladribine (phase III trial);
7 without
T6: 29; T12: 29;
T24: 26
2.38/0.99
NTZ cohort
(n 5 11)
38/12 10 F/1 M 6/10.5 3/2.75 6/4.5 7 IFN-b; 3 GA; 1 mitoxantrone T6: 6; T12: 11;
T24: 9
NA
Other treatment
cohort (n 5 11)
37.5/13 9 F/2 M 1.5/11 1.5/1 2/2.5 2 IFN-b; 1 GA; 8 without T6: 11; T12: 5;
T24: 0
NA
Abbreviations: EDSS 5 Expanded Disability Status Scale; FTY 5 fingolimod; GA 5 glatiramer acetate; IFN-b 5 interferon-b; NA 5 not available; NTZ 5
natalizumab.
Data represent median/interquartile range unless otherwise specified.
Table 2 Clinical data on the 2 patients with multiple sclerosis who underwent an HZ while receiving FTY treatment
Age at study
entry, y Sex
Disease
duration, y
EDSS
score
Total no. relapses
before starting
treatment
Previous
treatment
Zoster onset
(mo after
starting FTY)
Interval zoster
onset/blood
draw, d
VZV serology
index before
starting FTY
Involved
dermatoma
HZ 1 30 F 0.5 2.0 2 Nonea 5 118 1.82 C4
HZ 2 50.5 M 8.5 2.5 3 IFN-b 6 26 1.27 D8
Abbreviations: EDSS 5 Expanded Disability Status Scale; FTY 5 fingolimod; HZ 5 herpes zoster; IFN-b 5 interferon-b; VZV 5 varicella-zoster virus.
aHZ 1 received methylprednisolone 5 weeks before blood draw at T0.
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of study patients, we cannot rule out that milder differences
have gone unnoticed. Correlations between VZV serology
index and SFC counts obtained after VZV/IE63 or VZV lysate
stimulation were analyzed using the Spearman test. Probability
values ,0.05 were considered significant. All statistical
analyses were performed with GraphPad Prism version 6.04
(GraphPad Software, La Jolla, CA).
RESULTS Before treatment onset, the 3 groups of
patients showed comparable CD31 T lymphocyte
Figure 1 Increased VZV/IE63-specific cellular immune response after 6 months of FTY treatment
Interferon-g–mediated cellular immune responses against pool of peptides encompassing the whole VZV/IE63 protein (A),
VZV viral lysate (B), pool of selected peptides of FLU (C), FLU viral lysate (D), and pool of peptides encompassing the whole
JCV VP-1 protein (E) were tested using enzyme-linked immunospot assay. Data were obtained before treatment initiation
(T0), and after 6 (T6), 12 (T12), and 24 months (T24) of treatment. Data of FTY-treated patients with multiple sclerosis
appear in black in the graphs, NTZ-treated patients in red, and patients under other DMTs in blue. Responses reached by the
2 patients who underwent an HZ during FTY treatment are represented as dots on the graphs. Box and whisker plots show
median, 25th and 75th percentiles, and range. The mean is represented as a dot in the box. The effect of the treatment
duration for each treated group was assessed in a Kruskal–Wallis test. If significant, T0 was then compared to subsequent
time points using pairwise unparametric Wilcoxon tests corrected for Bonferroni multiple comparisons. The asterisks
represent differences for the effect of time for a given treatment. In all of these experiments, only data of FTY-treated
patients at T6 and for IE63 reached significance; **P,0.01. FLU5 influenza virus; FLU pool5 FLU pool of CD81 restricted
peptides; FTY 5 fingolimod; HZ 5 herpes zoster; JCV 5 JC virus; JCV pool 5 JCV VP-1 protein; NTZ 5 natalizumab;
others 5 other disease-modifying treatments (DMTs); SFC 5 spot-forming cell; VZV 5 varicella-zoster virus; VZV pool 5
VZV IE63 protein.
Neurology: Neuroimmunology & Neuroinflammation 3
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
frequencies among thawed PBMCs (median/inter-
quartile range 5 26.8%/20.3; pKW 5 0.477; figure
e-1 at Neurology.org/nn). No significant difference
was found between MS patient categories for age,
disease duration, and sex. However, significantly
fewer patients were treatment-naive at the start of
NTZ or FTY treatment than for IFN-b or
glatiramer acetate treatment, in accordance with
clinical practice. As expected, FTY induced a
marked lymphopenia at all time points tested,
reducing the median frequency of CD31 T cells by
83% to 89%, of CD41 T cells by 96%, and of CD81
T cells by 77% to 83%, as compared to T0. Neither
NTZ nor any other DMT statistically affected the
CD31 T cell population (figure e-1).
To assess whether FTY interferes with antiviral
immune responses, IFN-g secretion by PBMCs was
measured by ELISPOT upon VZV, FLU, and JCV
stimulations. Baseline responses were similar in all
groups tested whatever the antigen used (figure 1,
T0). Of main interest, as compared to T0, we de-
tected a 3.8-fold increase of the VZV/IE63-specific
cellular immune response in FTY-treated patients at
T6 (corrected Wilcoxon ranked test, p 5 0.0096),
which returned to normal at subsequent time points
(figure 1A, pKW5 0.0372). By contrast, FTY-treated
patients with MS did not present any increased cel-
lular immune response against VZV lysate (pKW 5
0.9654), JCV pool (pKW 5 0.1065), FLU pool
(pKW 5 0.2299), or FLU lysate (pKW 5 0.1452) at
any time point tested (figure 1, B–E). In addition, we
did not observe any difference in the viral-specific
cellular immune responses of patients on NTZ or
other DMTs. Of note, the 2 patients who had HZ
after 6 months of FTY treatment did not develop any
VZV/IE63-specific cellular immune response at the
time of HZ onset (figure 1A). Somewhat contrasting,
at the time of their HZ onset, the VZV lysate-specific
cellular immune response seemed to be normal (fig-
ure 1B, T6). It is of interest that we found a signif-
icant correlation at T0 between the VZV antibody
index and the VZV/IE63-specific but not the VZV
lysate-specific T cell response, pointing to the central
immunogenic role of IE63 (figure e-2).
DISCUSSION FTY-treated patients with MS have a
1.6-fold increased risk of developing HZ, as
compared to other patients with MS. The risk of
HZ is maximal at 6 months into treatment,
without any peculiar increase afterward.6 Adding to
this observation, serious or even fatal cases of
disseminated VZV infection were reported in FTY-
treated patients.3,6,14,15 However, the reason for such a
VZV reactivation is still poorly understood.
Herein, we show that, ex vivo, the cellular
immune response specific to VZV, JCV, and FLU
by ELISPOT assay is maintained in FTY-treated
patients as compared to control patients with MS.
However, there is a notable exception for VZV/
IE63-specific T cell response, which is clearly
increased after 6 months into FTY treatment as com-
pared to patients with MS who have other DMTs.
Yet, this 6-month time point precisely coincides with
the reported peak of HZ incidence.6
Of note, the 2 FTY-treated patients who devel-
oped HZ had an undetectable VZV/IE63-specific
cellular immune response at the time of the onset
of their HZ (T6). These results suggest that the
VZV/IE63-specific T cell response may be key in pre-
venting the onset of HZ in FTY-treated patients. A
slightly reduced antiviral T cell response has been pre-
viously found in patients treated with FTY whereby
11% of them had a subclinical reactivation of VZV
in the saliva. However, in contrast to our methods,
these authors did not normalize their data. Thus,
the question remains open whether the decreased
VZV-specific T cell response may simply reflect the
lymphopenia associated with VZV.8 Clearly support-
ing our data, others have found that a deficiency in
IE63-specific T cell response was associated with a
subclinical VZV reactivation in patients with malig-
nancies, whereas the immune response directed
against the VZV-glycoprotein gE was maintained in
the same group of patients.16
In conclusion, in this longitudinal observational
study with FTY-treated patients and control patients
with MS, we show that the overall viral-specific cellu-
lar immune response is preserved in FTY-treated pa-
tients with MS when normalized to the CD31 T cell
count. Our data further suggest that a VZV reactiva-
tion occurs at 6 months under FTY and that, at this
time, the VZV/IE63-specific cellular immune
response seems to be crucial in preventing the onset
of HZ under FTY treatment. To further establish that
VZV reactivation takes place at 6 months into FTY
treatment, it may be of interest for future studies to
encompass determination of VZVDNA and of VZV-
specific antibodies in the blood, and possibly also in
the CSF, at different time points. Such studies will
also tell whether the determination of the VZV/IE63-
specific cellular immune response may serve to iden-
tify patients at risk of HZ. Until then, and based on
our data, which show a correlation between the VZV/
IE63-specific cellular immune response and the VZV
antibody index, we suggest that it is important to
vaccinate future FTY-treated patients with MS who
have a low VZV antibody index.
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